<?xml version='1.0' encoding='utf-8'?>
<document id="23520311"><sentence text="Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients."><entity charOffset="0-14" id="DDI-PubMed.23520311.s1.e0" text="Clarithromycin" /><entity charOffset="25-34" id="DDI-PubMed.23520311.s1.e1" text="linezolid" /><pair ddi="false" e1="DDI-PubMed.23520311.s1.e0" e2="DDI-PubMed.23520311.s1.e0" /><pair ddi="false" e1="DDI-PubMed.23520311.s1.e0" e2="DDI-PubMed.23520311.s1.e1" /></sentence><sentence text="The use of linezolid for the treatment of multidrug-resistant tuberculosis is limited by dose- and time-dependent toxicity"><entity charOffset="11-20" id="DDI-PubMed.23520311.s2.e0" text="linezolid" /></sentence><sentence text=" Recently, we reported a case of pharmacokinetic drug-drug interaction between linezolid and clarithromycin that resulted in increased linezolid exposure"><entity charOffset="79-88" id="DDI-PubMed.23520311.s3.e0" text="linezolid" /><entity charOffset="93-107" id="DDI-PubMed.23520311.s3.e1" text="clarithromycin" /><entity charOffset="135-144" id="DDI-PubMed.23520311.s3.e2" text="linezolid" /><pair ddi="false" e1="DDI-PubMed.23520311.s3.e0" e2="DDI-PubMed.23520311.s3.e0" /><pair ddi="false" e1="DDI-PubMed.23520311.s3.e0" e2="DDI-PubMed.23520311.s3.e1" /><pair ddi="false" e1="DDI-PubMed.23520311.s3.e0" e2="DDI-PubMed.23520311.s3.e2" /><pair ddi="false" e1="DDI-PubMed.23520311.s3.e1" e2="DDI-PubMed.23520311.s3.e1" /><pair ddi="false" e1="DDI-PubMed.23520311.s3.e1" e2="DDI-PubMed.23520311.s3.e2" /></sentence><sentence text=" The aim of this prospective pharmacokinetic study is to quantify the effect of clarithromycin on the exposure of linezolid"><entity charOffset="80-94" id="DDI-PubMed.23520311.s4.e0" text="clarithromycin" /><entity charOffset="114-123" id="DDI-PubMed.23520311.s4.e1" text="linezolid" /><pair ddi="false" e1="DDI-PubMed.23520311.s4.e0" e2="DDI-PubMed.23520311.s4.e0" /><pair ddi="false" e1="DDI-PubMed.23520311.s4.e0" e2="DDI-PubMed.23520311.s4.e1" /></sentence><sentence text=" Subjects were included in an open-label, single-centre, single-arm, fixed-order pharmacokinetic interaction study" /><sentence text=" All subjects received 300 mg linezolid twice daily during the entire study, consecutively co-administered with 250 mg and 500 mg clarithromycin once daily"><entity charOffset="30-39" id="DDI-PubMed.23520311.s6.e0" text="linezolid" /><entity charOffset="130-144" id="DDI-PubMed.23520311.s6.e1" text="clarithromycin" /><pair ddi="false" e1="DDI-PubMed.23520311.s6.e0" e2="DDI-PubMed.23520311.s6.e0" /><pair ddi="false" e1="DDI-PubMed.23520311.s6.e0" e2="DDI-PubMed.23520311.s6.e1" /></sentence><sentence text=" Steady-state serum curves of linezolid and clarithromycin were analysed using validated methods, and differences between pharmacokinetic parameters were calculated"><entity charOffset="30-39" id="DDI-PubMed.23520311.s7.e0" text="linezolid" /><entity charOffset="44-58" id="DDI-PubMed.23520311.s7.e1" text="clarithromycin" /><pair ddi="false" e1="DDI-PubMed.23520311.s7.e0" e2="DDI-PubMed.23520311.s7.e0" /><pair ddi="false" e1="DDI-PubMed.23520311.s7.e0" e2="DDI-PubMed.23520311.s7.e1" /></sentence><sentence text=" Linezolid exposure increased by a median (interquartile range) of 44% (23-102%, p=0"><entity charOffset="1-10" id="DDI-PubMed.23520311.s8.e0" text="Linezolid" /></sentence><sentence text="043) after co-administration of 500 mg clarithromycin (n=5) compared to baseline, whereas 250 mg clarithromycin had no statistically significant effect"><entity charOffset="39-53" id="DDI-PubMed.23520311.s9.e0" text="clarithromycin" /><entity charOffset="97-111" id="DDI-PubMed.23520311.s9.e1" text="clarithromycin" /><pair ddi="false" e1="DDI-PubMed.23520311.s9.e0" e2="DDI-PubMed.23520311.s9.e0" /><pair ddi="false" e1="DDI-PubMed.23520311.s9.e0" e2="DDI-PubMed.23520311.s9.e1" /></sentence><sentence text=" Co-administration was well tolerated by most patients; none experienced severe adverse effects" /><sentence text=" One patient reported common toxicity criteria grade 2 gastrointestinal adverse events" /><sentence text=" In this study, we showed that clarithromycin significantly increased linezolid serum exposure after combining clarithromycin with linezolid in multidrug-resistant tuberculosis patients"><entity charOffset="31-45" id="DDI-PubMed.23520311.s12.e0" text="clarithromycin" /><entity charOffset="70-79" id="DDI-PubMed.23520311.s12.e1" text="linezolid" /><entity charOffset="111-125" id="DDI-PubMed.23520311.s12.e2" text="clarithromycin" /><entity charOffset="131-140" id="DDI-PubMed.23520311.s12.e3" text="linezolid" /><pair ddi="false" e1="DDI-PubMed.23520311.s12.e0" e2="DDI-PubMed.23520311.s12.e0" /><pair ddi="false" e1="DDI-PubMed.23520311.s12.e0" e2="DDI-PubMed.23520311.s12.e1" /><pair ddi="false" e1="DDI-PubMed.23520311.s12.e0" e2="DDI-PubMed.23520311.s12.e2" /><pair ddi="false" e1="DDI-PubMed.23520311.s12.e0" e2="DDI-PubMed.23520311.s12.e3" /><pair ddi="false" e1="DDI-PubMed.23520311.s12.e1" e2="DDI-PubMed.23520311.s12.e1" /><pair ddi="false" e1="DDI-PubMed.23520311.s12.e1" e2="DDI-PubMed.23520311.s12.e2" /><pair ddi="false" e1="DDI-PubMed.23520311.s12.e1" e2="DDI-PubMed.23520311.s12.e3" /><pair ddi="false" e1="DDI-PubMed.23520311.s12.e2" e2="DDI-PubMed.23520311.s12.e2" /><pair ddi="false" e1="DDI-PubMed.23520311.s12.e2" e2="DDI-PubMed.23520311.s12.e3" /></sentence><sentence text=" The drug-drug interaction is possibly P-glycoprotein-mediated" /><sentence text=" Due to large interpatient variability, therapeutic drug monitoring is advisable to determine individual effect size" /><sentence text=" " /></document>